Motiei Marjan, Abu-Dawud Raed, Relógio Angela, Assaf Chalid
Institute for Molecular Medicine, MSH Medical School Hamburg, Hamburg 20457, Germany.
Institute for Systems Medicine, and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg 20457, Germany.
EBioMedicine. 2024 Dec;110:105451. doi: 10.1016/j.ebiom.2024.105451. Epub 2024 Nov 19.
The circadian clock, a fundamental cellular mechanism, regulates the rhythmic expression of numerous genes and biological processes across various organs. Disruptions in this system, driven by genetic or environmental factors, have been reported to be involved in cancer progression. This review explores the role of the circadian clock in cancer hallmarks and its impact on cellular homeostasis within haematological malignancies. Drawing on findings from in vitro, in vivo, and clinical trials, this review highlights the potential of clock genes as diagnostic and prognostic biomarkers, and as therapeutic targets for optimising treatment timing. It discusses how circadian rhythms can enhance treatment efficacy through both pharmacological and non-pharmacological interventions, outlining strategies for optimising dosing schedules and implementing personalised chronobiological interventions, with a particular focus on haematological malignancies, including cutaneous lymphoma. Ongoing research holds promise for advancing personalised therapeutic approaches and ultimately improving cancer care standards.
生物钟是一种基本的细胞机制，可调节多个器官中众多基因的节律性表达以及生物过程。据报道，由遗传或环境因素驱动的该系统紊乱与癌症进展有关。本综述探讨了生物钟在癌症特征中的作用及其对血液系统恶性肿瘤细胞内稳态的影响。基于体外、体内研究及临床试验的结果，本综述强调了生物钟基因作为诊断和预后生物标志物以及优化治疗时机的治疗靶点的潜力。它讨论了昼夜节律如何通过药理学和非药理学干预提高治疗效果，概述了优化给药方案和实施个性化时间生物学干预的策略，尤其关注血液系统恶性肿瘤，包括皮肤淋巴瘤。正在进行的研究有望推进个性化治疗方法并最终提高癌症护理标准。
